Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148375 | 0.82 | MCL1 (0.35) | MCL1KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL6316182 | 0.81 | HSD17B10 (0.46) | MCL1KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL29463989 | 0.81 | HSD17B10 (0.46) | MCL1KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL20530598 | 0.78 | CYP1A2 (0.48) | L3MBTL1HPGDHSD17B10CYP3A4RAB9A | |
| SCHEMBL8585842 | 0.76 | HPRT1 (0.58) | MCL1KDM4EGAAMAPTCHEK1 | |
| SCHEMBL31016039 | 0.76 | HPRT1 (0.58) | MCL1KDM4EGAAMAPTCHEK1 | |
| SCHEMBL14406000 | 0.73 | MAPT (0.38) | MCL1KDM4EMAPTL3MBTL1HPGD | |
| SCHEMBL14406007 | 0.73 | KMT2A (0.40) | MCL1MAPTHPGDCYP3A4CYP1A2 | |
| SCHEMBL29364795 | 0.72 | SIGMAR1 (0.63) | MCL1KDM4EGAAMAPTCHEK1 | |
| SCHEMBL29555314 | 0.72 | SIGMAR1 (0.63) | MCL1KDM4EGAAMAPTCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983393-B1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-02 | — | — | EP | disclosed |
| US-12145961-B2 | Spirobicyclic analogues | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-19 | — | — | US | disclosed |
| EP-4385996-A2 | NOVEL SPIROBICYCLIC ANALOGUES | JANSSEN Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | disclosed |
| US-11999993-B2 | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-04 | — | — | US | disclosed |
| EP-3720865-B1 | NOVEL SPIROBICYCLIC ANALOGUES | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-13 | — | — | EP | disclosed |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| EP-3585904-B1 | USE OF BIOMARKERS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-20230303612-A1 | Novel Spirobicyclic Analogues | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-28 | — | — | US | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3974428-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2022-03-30 | — | — | EP | disclosed |
| US-20210380627-A1 | Novel Spirobicyclic Analogues | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-09 | — | — | US | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| US-11059850-B2 | Spirobicyclic analogues | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-13 | — | — | US | disclosed |
| US-20200369707-A1 | NOVEL SPIROBICYCLIC ANALOGUES | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2020-11-26 | — | — | US | disclosed |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-19 | — | — | US | disclosed |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20190263833-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-29 | — | — | US | disclosed |
| US-20180243328-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369707-A1 | NOVEL SPIROBICYCLIC ANALOGUES | PRMT5, SIRT5, HDAC5 | MCL1 3911/4885KDM4E 69/4885GAA 4804/4885 |
| US-20190263833-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT8 | MCL1 1171/4885KDM4E 47/4885GAA 4056/4885 |
| US-20210380627-A1 | Novel Spirobicyclic Analogues | PRMT5, SIRT5, HDAC5 | MCL1 3911/4885KDM4E 69/4885GAA 4804/4885 |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | MCL1 1418/4885KDM4E 47/4885GAA 2961/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | MCL1 2076/4885KDM4E 61/4885GAA 3367/4885 |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | MCL1 1368/4885KDM4E 40/4885GAA 3122/4885 |
| US-20230303612-A1 | Novel Spirobicyclic Analogues | PRMT5, SIRT5, HDAC5 | MCL1 3911/4885KDM4E 69/4885GAA 4804/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | MCL1 2061/4885KDM4E 61/4885GAA 3313/4885 |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | MCL1 1418/4885KDM4E 47/4885GAA 2961/4885 |
| US-11059850-B2 | Spirobicyclic analogues | PRMT5, HDAC5, SIRT5 | MCL1 3856/4885KDM4E 68/4885GAA 4773/4885 |
| US-20180243328-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | MCL1 1864/4885KDM4E 53/4885GAA 3005/4885 |
| US-12145961-B2 | Spirobicyclic analogues | PRMT5, HDAC5, SIRT5 | MCL1 3856/4885KDM4E 68/4885GAA 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.